The pharmaceutical industry is always in a state of dynamic evolution. Scientific discoveries and commercial innovations build upon past achievements, with major breakthroughs continually reshaping the market landscape. Over the past year, the leaders driving these changes have achieved remarkable results, with their influence spanning research and development, manufacturing, regulation, and patient services.

GLP-1 receptor agonists, initially used primarily for diabetes treatment, have now shifted to the obesity field with phenomenal success. Advances in gene therapy have led to the approval of the first CRISPR gene-editing drug. In oncology, CAR-T cell therapy is overcoming production bottlenecks through off-the-shelf products, potentially expanding accessibility. Emerging artificial intelligence and machine learning tools are increasingly permeating broad aspects of pharmaceutical operations.

Against the backdrop of overall industry progress, the pharmaceutical ecosystem is also adapting to shifts in the market landscape—the recovery of the biotechnology sector,the Inflation Reduction Act's new pricing regulations, and ongoing efforts to advance equity goals together shape the current industry environment.

This year's PharmaVoice 100 list is a concentrated presentation of this ongoing wave of change. We honor those industry leaders who not only navigate change with ease but often pave new paths for others.

These most inspiring professionals in the industry fall into ten different categories: Standout Leaders, Clinical Trial Pros, Trailblazers, Patient Champions, Biotech Pathfinders, Cancer Care Visionaries, Cardiometabolic All-stars, Cell and Gene Therapy Pioneers, Rare Disease Warriors, and Tech and AI Wizards.

The following is the list of the 2024 PharmaVoice 100 honorees.

Editor's Note: This year we received hundreds of nominations, and the final selection was not an easy task. We sincerely thank the many leaders in the industry for nominating these inspiring figures in the pharmaceutical world.

Starting in 2025, we will no longer continue to publish the PharmaVoice 100 list. Instead, we will cover outstanding leaders throughout the year through a series of ongoing features. You are welcome tosubmit nominationsto recommend leaders you believe are worthy of attention.